The University of Cincinnati and the Physicians' Education Resource®, LLC, (PER®) and are both accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians, and have collaborated to design and execute these live and enduring educational activities.
For accreditation purposes, the University of Cincinnati is responsible for certification and documentation of attendance for this activity.
The University of Cincinnati is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The University of Cincinnati designates this live activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Not an official event of the 2017 ASCO Annual Meeting. Not sponsored or endorsed by ASCO or the Conquer Cancer Foundation.
This activity is supported by educational grants from Bayer HealthCare Pharmaceuticals Inc., Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and Lilly.
For further information concerning Lilly grant funding visit www.lillygrantoffice.com.
Salon A 1 & 2 (Lower Level)
720 S Michigan Avenue
Chicago, IL 60605
Are you prepared to provide state-of-the-art care to the next patient who presents to your clinic with a soft tissue sarcoma (STS)? Don’t miss this opportunity to learn about the breakthroughs occurring in STS from a renowned group of experts. Moving Forward From the Status Quo for the Treatment of Soft Tissue Sarcoma: Key Questions and New Answers to Optimize Outcomes is a case-based, CME-certified, live symposium to be held adjunct to an annual oncology meeting in Chicago, Illinois.
Historically poor outcomes in patients with metastatic STS have led to therapeutic nihilism among some physicians. However, a greater appreciation of the heterogeneous, complex biologies across the many STS subtypes, as well as the development of new and emerging therapeutic approaches, are transforming the ways in which these malignancies are managed. Optimal treatment requires a highly skilled, multidisciplinary team that encompasses medicine, pathology, radiology, and surgery.
Join us to learn about what’s on the horizon in STS, and to gain up-to-date guidance on the delivery of cross-discipline care for patients with STS that leverages the resources of both community- and academic-based healthcare providers.
Key topics on the agenda include:
This educational program is directed toward medical, surgical, and radiation oncologists who manage patients with soft tissue sarcoma (STS). Nurse practitioners, physician assistants, nurses, and other healthcare professionals interested in the treatment and management of patients with STS are also invited to participate.
Upon completion of this activity, participants should be better prepared to:
George D. Demetri, MD
Professor of Medicine, Harvard Medical School
Director, Ludwig Center at Harvard
Director, Center for Sarcoma and Bone Oncology
Dana-Farber Cancer Institute
ONS: PER Forum™: Nursing Opportunities to Improve Outcomes With the Advent of PARP Inhibitors in the Care of Women’s Cancers
May 17, 2018
ONS: Working Group for Changing Standards in EGFR-Mutated Lung Cancers: Real-World Applications of the Evidence for Nurses
May 17, 2018
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of Cancers
May 30, 2018
May 31, 2018
May 31, 2018